These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6639407)

  • 1. Pergolide in Parkinson's disease.
    Goetz CG; Tanner CM; Glantz R; Klawans HL
    Arch Neurol; 1983 Dec; 40(13):785-7. PubMed ID: 6639407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pergolide mesylate: lack of cardiac toxicity in patients with cardiac disease.
    Tanner CM; Chhablani R; Goetz CG; Klawans HL
    Neurology; 1985 Jun; 35(6):918-21. PubMed ID: 3889707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy of pergolide in patients with Parkinson's disease.
    Sage JI; Duvoisin RC
    Clin Neuropharmacol; 1986; 9(2):160-4. PubMed ID: 3708601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pergolide therapy for Parkinson's disease: neurobehavioral changes.
    Stern Y; Mayeux R; Ilson J; Fahn S; Cote L
    Neurology; 1984 Feb; 34(2):201-4. PubMed ID: 6538009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlled trial of pergolide mesylate in Parkinson's disease and progressive supranuclear palsy.
    Jankovic J
    Neurology; 1983 Apr; 33(4):505-7. PubMed ID: 6339985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term study of pergolide in Parkinson's disease.
    Jankovic J
    Neurology; 1985 Mar; 35(3):296-9. PubMed ID: 3974887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pergolide therapy in Parkinson's disease: a double-blind, placebo-controlled study.
    Sage JI; Duvoisin RC
    Clin Neuropharmacol; 1985; 8(3):260-5. PubMed ID: 3899352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind trial of pergolide for Parkinson's disease.
    Diamond SG; Markham CH; Treciokas LJ
    Neurology; 1985 Mar; 35(3):291-5. PubMed ID: 3883232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 6-month trial of pergolide mesylate in the treatment of idiopathic Parkinson's disease.
    Klawans HL; Tanner CM; Glatt S; Goetz CG
    Adv Neurol; 1983; 37():75-83. PubMed ID: 6344592
    [No Abstract]   [Full Text] [Related]  

  • 10. Pergolide therapy in Parkinson's disease.
    Jeanty P; Van den Kerchove M; Lowenthal A; De Bruyne H
    J Neurol; 1984; 231(3):148-52. PubMed ID: 6481422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical study of pergolide in Parkinson's disease].
    Gonce M; Delwaide PJ
    Presse Med; 1985 Jun; 14(26):1409-11. PubMed ID: 3161045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pergolide and lisuride in advanced Parkinson's disease.
    Lieberman AN; Gopinathan G; Neophytides A; Leibowitz M; Goldstein M
    Adv Neurol; 1984; 40():503-7. PubMed ID: 6695627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of pergolide mesylate, an ergoline, in animal models of Parkinson's disease: implications for therapy.
    Koller WC; Diamond BI; Weiner WJ; Nausieda PA; Klawans HL
    Trans Am Neurol Assoc; 1979; 104():161-4. PubMed ID: 553398
    [No Abstract]   [Full Text] [Related]  

  • 14. Pergolide in the treatment of Parkinson's disease.
    Mear JY; Barroche G; de Smet Y; Weber M; Lhermitte F; Agid Y
    Neurology; 1984 Jul; 34(7):983-6. PubMed ID: 6539880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of pergolide, a potent dopamine agonist, in Parkinson's disease.
    Lieberman AN; Goldstein M; Neophytides A; Leibowitz M; Gopinathan G; Walker R; Pact V
    Clin Pharmacol Ther; 1982 Jul; 32(1):70-5. PubMed ID: 7083733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide.
    Goetz CG; Tanner CM; Glantz RH; Klawans HL
    Neurology; 1985 May; 35(5):749-51. PubMed ID: 3990974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment with pergolide: decreased efficacy with time.
    Lieberman AN; Goldstein M; Leibowitz M; Gopinathan G; Neophytides A; Hiesiger E; Nelson J; Walker R
    Neurology; 1984 Feb; 34(2):223-6. PubMed ID: 6538014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lisuride and pergolide in Parkinson's disease.
    Lang AE; Sheehy MP; Quinn NP; Brincat S; Marsden CD; Parkes D
    Adv Neurol; 1983; 37():109-20. PubMed ID: 6858769
    [No Abstract]   [Full Text] [Related]  

  • 19. Mesulergine and pergolide in previously untreated Parkinson's disease.
    Wright A; Lees AJ; Stern GM
    J Neurol Neurosurg Psychiatry; 1987 Apr; 50(4):482-4. PubMed ID: 3585362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pergolide mesylate: a potent day-long inhibitor of prolactin in rhesus monkeys and patients with Parkinson's disease.
    Kleinberg DL; Lieberman A; Todd J; Greising J; Neophytides A; Kupersmith M
    J Clin Endocrinol Metab; 1980 Jul; 51(1):152-4. PubMed ID: 6769937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.